Figures & data
Table 1. Neurohormonal activity pathway.
Table 2. Myocardial necrosis and remodeling pathways.
Table 3. Renal dysfunction pathway.
Table 4. Inflammation, oxidative stress, and ECM pathways.
Savarese G, Musella F, D’Amore C, et al. Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure A Meta-Analysis. Jacc-Heart Fail. 2014 Apr;2(2):148–158 Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003 Mar 11;107(9):1278–1283. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002 May 21;105(20):2392–2397. Aimo A, Januzzi JL Jr., Vergaro G, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: an Individual Patient Data Meta-Analysis. Circulation. 2018 Jan 16;137(3):286–297. Aimo A, Vergaro G, Passino C, et al. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: a Meta-Analysis. JACC Heart Fail. 2017 Apr;5(4):280–286. Emdin M, Aimo A, Vergaro G, et al. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. J Am Coll Cardiol. 2018 Nov 6;72(19):2309–2320. Pacho C, Domingo M, Nunez R, et al. Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. BMC Geriatr. 2018 May 9;18(1):109. Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007 Sep 11;50(11):1054–1060. Fernandez ABM, Ferrero-Gregori A, Garcia-Osuna A, et al. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction. ESC Heart Fail. 2020 Oct;7(5):2223–2229. Luo JW, Duan WH, Song L, et al. A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure. Front Cardiovasc Med.2021 Nov;5:8. French B, Wang L, Ky B, et al. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. J Card Fail. 2016 Apr;22(4):256–262. Dupont M, Wu YP, Hazen SL, et al. Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events. Circ-Heart Fail. 2012 Sep;5(5):602–609 Wang CH, Han S, Tong F, et al. Predictive Value of the Serum Cystatin C/Prealbumin Ratio in Combination With NT-proBNP Levels for Long-Term Prognosis in Chronic Heart Failure Patients: a Retrospective Cohort Study. Front Cardiovasc Med. Vol. 14. 2021 Jul; p. 8. Bayes-Genis A, Barallat J, Galan A, et al. Soluble Neprilysin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure Patients. J Am Coll Cardiol. 2015 Feb 24;65(7):657–665. Gommans DHF, Revuelta-Lopez E, Lupon J, et al. Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure. Jacc-Heart Fail. 2021 Feb;9(2):85–95 Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure - Prognostic value and the effect of valsartan. Circulation. 2005 Sep 6;112(10):1428–1434. Pellicori P, Zhang J, Cuthbert J, et al. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc Res. 2020 Jan 1;116(1):91–100. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998 Feb;31(2):391–398. Tang WH, Shrestha K, Troughton RW, et al. Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest Heart Fail. 2011 May-Jun;17(3):105–109. George J, Patal S, Wexler D, et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J. 2005 Sep;150(3):484–487. Chang YY, Chen AR, Wu XM, et al. Comparison the Prognostic Value of Galectin-3 and Serum Markers of Cardiac Extracellular Matrix Turnover in Patients with Chronic Systolic Heart Failure. Int J Med Sci. 2014;11(11):1098–1106. van Boven N, Battes LC, Akkerhuis KM, et al. Toward personalized risk assessment in patients with chronic heart failure: detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study. Am Heart J. 2018 Feb;196:36–48.